Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.
J Hepatol. 2013 Sep;59(3):510-7. doi: 10.1016/j.jhep.2013.04.028. Epub 2013 May 9.
BACKGROUND & AIMS: To investigate diagnostic and prognostic values of sulfite oxidase (SUOX) in patients with hepatocellular carcinoma (HCC) who underwent curative resection.
We investigated immunohistochemically the expression dynamics of SUOX, aldo-ketoreductase family 1 member B10 (AKR1B10) and CD34 at different stages of HCC. The differential diagnostic performance of three markers or their combinations in high-grade dysplastic nodules (HGDNs) and well-differentiated small HCC (WD-sHCC) were investigated by logistic regression models and validated in an independent testing set. Overall survival (OS) and time to recurrence (TTR) were evaluated in 300 patients with HCC as the testing cohort, and validated in 198 patients with HCC.
SUOX was decreased and AKR1B10 and CD34 were increased with the stepwise progression of hepatocarcinogenesis. For differential diagnosis of WD-sHCC from HGDNs, the sensitivity and specificity of the SUOX+AKR1B10+CD34 combination for WD-sHCC detection were 93.8% and 95.2%, respectively, and overall accuracy was much higher than any of the three individual markers and two marker combinations. In addition, SUOX, but not AKR1B10 and CD34, was an independent prognostic factor for OS and TTR, and showed better correlation with OS and TTR if combined with serum α-fetoprotein (AFP) for both the testing and validation cohorts.
SUOX+AKR1B10+CD34 combination could make a substantial contribution to hepatic immunopathological diagnosis to distinguish WD-sHCC from HGDNs. Meanwhile, SUOX combined with serum AFP may predict postoperative outcome and tumor recurrence risk.
研究亚硫酸氧化酶（SUOX）在接受根治性切除术的肝细胞癌（HCC）患者中的诊断和预后价值。
我们用免疫组化方法研究了 SUOX、醛酮还原酶家族 1 成员 B10（AKR1B10）和 CD34 在 HCC 不同阶段的表达动态。通过逻辑回归模型研究了这三种标志物或其组合在高级别异型增生结节（HGDNs）和低分化小 HCC（WD-sHCC）中的鉴别诊断性能，并在独立测试集中进行了验证。我们将 300 例 HCC 患者作为检测队列评估总生存期（OS）和无复发生存时间（TTR），并在 198 例 HCC 患者中进行了验证。
随着肝癌发生的逐步进展，SUOX 减少，AKR1B10 和 CD34 增加。对于 WD-sHCC 与 HGDNs 的鉴别诊断，SUOX+AKR1B10+CD34 组合检测 WD-sHCC 的敏感性和特异性分别为 93.8%和 95.2%，总准确率明显高于任何三种单独标志物和两种标志物组合。此外，SUOX 是 OS 和 TTR 的独立预后因素，而 AKR1B10 和 CD34 不是，并且与 OS 和 TTR 的相关性更好，如果将其与血清甲胎蛋白（AFP）结合，无论是在检测队列还是验证队列中，均如此。
SUOX+AKR1B10+CD34 组合可对 WD-sHCC 与 HGDNs 进行肝免疫病理学诊断，具有重要贡献。同时，SUOX 联合血清 AFP 可能预测术后结局和肿瘤复发风险。
